Video Gallery

About this Video

When could society tackle the twin epidemics of starvation and obesity? 50 years? 100 years? What about today?

Geoff von Maltzahn from Flagship VentureLabs explains how their team harnessed the power of technology, biology, and economics to launch Pronutria- a company that takes a system approach to the twin crises of malnutrition and is developing a new solution with the potential to improve nutrition globally in a sustainable, cost-effective way. By identifying the best proteins in food and designing low-cost, low-input methods of producing these proteins– all without requiring arable land, Pronutria could provide essential protein nutrition to every person on Earth with only a piece of land the size of Rhode Island.

Geoffrey von Maltzahn, PhD, is an award winning biological engineer, inventor, and entrepreneur, a Principal in Flagship VentureLabs, and a founder of multiple biotech companies including Pronutria, Seres Health, and Sienna Labs.


About the Speaker

Geoffrey von Maltzahn

Geoffrey von Maltzahn

Geoff is a founder of startups that have achieved over $4 billion in public and private market capitalization. These include Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Axcella Health, Kaleido Biosciences, and Sienna Biopharmaceuticals (NASDAQ: SNNA), which respectively are pioneering plant microbiome products for crop improvement, microbiome therapeutics, amino acid-based drugs, novel chemistries to shape the human microbiome, and innovative medical dermatology products.

Geoff is Partner in Flagship Pioneering, Chief Innovation Officer of Kaleido Biosciences, and Chief Innovation Officer of Indigo. He recently served as CEO of Kaleido Biosciences, where he led the company from inception to launching multiple clinical programs, and as President of Indigo, where he built the company’s technology platform and led the development of the company’s Indigo Cotton and Wheat commercial products. He was previously the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and build-out of the company’s discovery platform, and Vice President, Discovery of Axcella Health, where he led the discovery of two therapeutic products in human trials.

His work has led to over 100 patent applications and patents, 20 peer-reviewed publications, as well as over 20 awards and honors, including Business Insider’s 30 under 40 young leaders that are shaping the future of medicine and the prestigious Lemelson-MIT Student Prize for invention and innovation. Geoff also has had his inventions recognized by the World Economic Forum, Forbes, CNN, Technology Review, and among the “greatest scientific breakthroughs of today” by Dean Kamen on Planet Green and in the Innovations of the Year by MSNBC.